Nuo Therapeutics

Nuo Therapeutics, Inc. (OTC: NURO) is a medical device company that has developed the MIST Therapy system — a non-contact, low-frequency ultrasound wound care treatment that uses ultrasonic energy to promote healing in chronic wounds including diabetic foot ulcers, venous stasis ulcers, pressure injuries, and other difficult-to-heal wound types. According to its website at nuotherapeutics.com, the MIST Therapy system delivers low-frequency ultrasound energy to wound surfaces through a saline mist that acts as a coupling medium, stimulating cellular activity, reducing bacterial bioburden, and promoting wound healing through biological mechanisms that include stimulation of angiogenesis, reduction of wound-bed inflammation, and enhancement of growth factor activity. The non-contact delivery mode eliminates patient discomfort from direct wound manipulation and allows treatment of wounds that cannot tolerate contact-based treatment modalities.

Nuo Therapeutics' MIST Therapy system, described at nuotherapeutics.com, has received FDA clearance for the promotion of healing in chronic wounds and has been used in wound care clinics, hospital wound care departments, long-term care facilities, and home health settings across the United States. The system's clinical evidence base includes multiple peer-reviewed studies demonstrating wound healing outcomes in diabetic foot ulcers and other chronic wound types that are consistent with the biological mechanisms through which low-frequency ultrasound promotes tissue repair. MIST Therapy's non-contact, painless application and ability to treat biofilm-containing wounds — where bacterial biofilms are a major barrier to healing — addresses practical clinical challenges that limit the effectiveness of alternative wound care treatment modalities.

Nuo Therapeutics markets the MIST Therapy system to wound care clinicians through its commercial organization, targeting wound care centers, hospital-based wound programs, and other healthcare settings where the treatment of chronic non-healing wounds represents a significant clinical and economic challenge. According to nuotherapeutics.com, the company's commercial strategy focuses on building clinical awareness of MIST Therapy's evidence base and clinical utility among wound care specialists, supporting reimbursement access through Medicare and private payer coverage for ultrasound wound care treatment, and expanding utilization of the MIST Therapy system across wound care settings. Nuo Therapeutics' combination of non-contact ultrasound wound care technology, FDA-cleared wound healing indication, clinical evidence base, and wound care market focus positions it as a specialized medical device company addressing the significant clinical challenge of chronic wound management.